Meeting
2020 ASCO Virtual Scientific Program
Demonstrating the value of liquid biopsy for lung cancer in a public health care system.
Authors
Rosalyn A. Juergens
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
Rosalyn A. Juergens , Doreen Anuli Ezeife , Janessa J. Laskin , Jason Scott Agulnik , Desiree Hao , Scott Andrew Laurie , Jennifer H. Law , Lisa W Le , Lesli Ann Kiedrowski , Frances A. Shepherd , Victor Cohen , Aria Shokoohi , Rachel Vandermeer , Janice Juanning Li , Inna Hanson , Roxanne Fernandes , Alexandra Maria Salvarrey , Richard B. Lanman , Natasha B. Leighl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Clinical Trial Registration Number
NCT03576937
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3546)
DOI
10.1200/JCO.2020.38.15_suppl.3546
Abstract #
3546
Poster Bd #
276
Abstract Disclosures
Similar Posters
First Author: Barbara J. Gitlitz
Poster
2015 ASCO Annual Meeting
Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).
First Author: Mark G. Kris
First Author: Barbara J. Gitlitz
Poster
2014 ASCO Annual Meeting
Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.
First Author: Alexander E. Drilon